ViewRay Inc., a Cleveland-based medical device company, has raised $15 million in fresh funding, raising the total amount raised by the company to nearly $100 million. The company’s machinery, which can produce real-time images of cancerous tumors while the tumors are being treated radiation, raised what has been in its biggest round, a $45 million Series C, last year. ViewRay’s investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital.

Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.

AxioMed Spine Corporation, a spinal orthopedics company has closed its Series D financing, raising $5 million in two tranches from current and new investors. This funding boosts the previously announced $15 million Series D financing. Investors in the business include Siemens Venture Capital, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors. PRESS RELEASE [...]

Akebia Therapeutics Inc., a pharmaceutical company focused on treatments for anemia, has drawn down a $4.1 million tranche of its previously announced Series B financing. Investors included Novartis Bioventures, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.

Cincinnati-based Akebia Therapeutics has closed on $22 million in Series B financing. Existing shareholders Novartis Venture Fund and Venture Investors co-led the round, which also saw participation from Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital and new investors including AgeChem Venture Fund. Akebia develops pharmaceuticals focused on anemia and vascular disorders. The $22 million Series B round includes a $14 million first closing. In addition, the company has the right to access another $8 million through the end of 2011.

AxioMed Spine, which manufactures artificial disc replacements for medical patients, received $500,000 in the form of a loan from the state of Ohio to continue developing an artificial cervical spine disc. The company has raised $56 million to date from investors including Siemens Venture Capital GmbH, Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors.